Ph.D. Psychology, University of Kentucky
M.A. Psychology, Unidersity of Kentucky
B.A. Psychology, Davidson College
Dr. Stoops continued his work as principal investigator on three NIDA-funded grants (R01 DA 036553, R01 DA 043938 and R21 DA 035376) and one NIAAA-funded grant (R21 AA 026129) in 2018. Dr. Stoops served as a co-Investigator or consultant on over ten other funded project, including the University of Kentucky Center for Clinical and Translational Science (CCTS). He published four peer-reviewed manuscripts, two as senior author. He presented at the College on Problems of Drug Dependence and the Research Society on Alcoholism 2018 meetings. He was also invited to speak at University of New Mexico Center for Alcoholism, Substance Abuse and Addictions, Morehead State University Department of Psychology and Pennsylvania State University Department of Psychiatry. Lastly, he was featured on the mainstage at the American Psychological Association 2018 Convention for his insights on psychology's response to the opioid epidemic. Dr. Stoops continued his leadership roles as Director of the Regulatory Knowledge and Support Core and Component Lead for Research Methods of the UK CCTS. Dr. Stoops also maintained his strong commitment to service to the field at a national level in 2018, including 1) serving as Past Chair the Board of Convention Affairs of the American Psychological Association, 2) serving as Program Chair of the College on Problems of Drug Dependence, 3) serving on the Board of Directors of the College on Problems of Drug Dependence, 4) serving on the Interventions to Prevent and Treat Addiction NIH study section, 5) serving as the American Psychological Association Division 28 (Psychopharmacology and Substance Abuse) Council Representative) and 6) serving as editor of Experimental and Clinical Psychopharmacology.
A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder (R21AA026129). National Institute on Alcohol Abuse and Alcoholism.
Selective Monoamine Release as a Treatment for Cocaine Use Disorders (R01DA036553). National Institute on Drug Abuse.
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use (R01DA043938). National Institute on Drug Abuse.
Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis (R21DA035376). National Institute on Drug Abuse.
Czoty, P.W., Stoops, W.W.* and Rush, C.R. (2016). Evaluation of the “Pipeline” for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory and Clinical Trial Research. Pharmacological Reviews, 68, 533-562. *Authors Czoty and Stoops contributed equal effort on this manuscript.
Strickland, J.C., Beckmann, J.S., Rush, C.R. and Stoops, W.W. (2017). A Pilot Study of Loss Aversion for Drug and Non-Drug Commodities in Cocaine Users. Drug and Alcohol Dependence, 180, 223-226.
Strickland, J.C. and Stoops, W.W. (2018). Feasibility, Acceptability and Validity of Crowdsourcing for Collecting Longitudinal Alcohol Use Data. Journal of Experimental Analysis of Behavior, 110, 136-153.
Strickland, J.C. and Stoops, W.W. (2018). Evaluating Autonomy, Beneficence and Justice with Substance-Using Populations: Implications for Clinical Research. Psychology of Addictive Behaviors, 32, 552-563.